Arch Biopartners hires U.S. lab to advance pre-IND IL-32 kidney program

The biotech company said the work will generate proprietary data for its diabetic kidney disease candidates and patent claims, while also disclosing ongoing market-making services from Red Cloud Securities.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.